Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer

Summary

Principal Investigator: S A Mousa
Abstract: [unreadable] DESCRIPTION (provided by applicant): The development of resistance to chemotherapy represents an adaptive biological response by tumor cells that leads to treatment failure and patient relapse. There is an urgent need to overcome this problem if treatments are to be successful in eradicating tumors. Tumor cell irreversible growth arrest (senescence) is an early cellular response to the stress of exposure to chemotherapeutic agents. Those cells that are able to bypass senescence ultimately exhibit resistance to chemotherapy. Recent reports provide a persuasive rationale for studying the role of cathepsin L in the process of chemotherapeutic drug resistance. We showed that specific targeting of cathepsin L using chemical inhibitors or siRNA to this molecule forced cancer cells into a state of irreversible growth arrest and suppressed development of resistance to drugs. We also demonstrated the ability of cathepsin L inhibitor to reverse drug resistance in vivo utilizing nude mice bearing xenografts of doxorubicin resistant neuroblastoma cell line SKN-SH/R drug resistant tumors. Because many chemotherapeutic agents show systemic toxicities, and because cathepsin L inhibitors to be used in these studies are peptides subject to biodegradation, we will address these limitations by encapsulation of agents using PEG-PLGA nanoparticles targeted to either the sites of tumor neovascularization (1v integrin) or to MCF7 tumor cells via HER2 antibody. Female nude mice will have drug-resistant MCF7 human breast cancer cells implanted orthotopically into the fourth mammary gland. We will study two commercially available Cathepsin L inhibitors, Z-Phe-Try (t-Bu)-diazomethylketone and 1-Naphthalenesulfonyl-Ile-Trp- Aldehyde given either alone or with doxorubicin with respect to their effects on tumor cell growth and drug-resistance. Specific Aim 1: Prior to performance of nanoparticle-targeted therapy studies in nude mice, preliminary experiments to determine optimum formulations of nanoparticles will be performed in vivo in the chick chorioallantoic membrane (CAM) tumor implant model of tumor angiogenesis and growth. This model permits in vivo pre-screening for bioactivity while limiting the use of more sentient and costly murine species. Specific Aim 2: Nanoparticle formulations that show optimum anti-tumor and anti-angiogenesis activity in the CAM model will be tested in the mouse breast cancer model. In these studies, we will evaluate the effectiveness of cathepsin L inhibitors in reducing doxorubicin resistance as evidenced by improved anti-tumor activities. Comparisons will be made between non-targeted and targeted therapies with respect to anti-tumor efficacy and doxorubicin-associated toxicities. Cancer cells have the unique ability to develop resistance to chemotherapeutic drugs, and so research on ways to reverse this phenomenon would have significant value in the treatment of cancer patients. This project will use a combination of two drugs, one of which impairs the cancer cell's ability to develop drug resistance, in a mouse model of breast cancer. A novel technology, the use of nanoparticles to encapsulate the test drugs, will be tested to determine whether these nanoparticles can improve the delivery of drugs and minimize the associated toxicities. [unreadable] [unreadable] [unreadable]
Funding Period: 2007-09-26 - 2009-08-31
more information: NIH RePORT

Top Publications

  1. ncbi Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy
    Xin Zheng
    Children s Memorial Research Center, Children s Memorial Hospital, Department of Pediatrics, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Biochim Biophys Acta 1783:2294-300. 2008
  2. pmc Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism
    Xin Zheng
    Department of Pediatrics, Children s Memorial Research Center, Children s Memorial Hospital, Chicago, IL, USA
    Am J Physiol Cell Physiol 296:C65-74. 2009
  3. ncbi The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor
    Abdelhadi Rebbaa
    The Pharmaceutical Research Institute at Albany, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA
    Anticancer Res 29:4473-81. 2009

Scientific Experts

  • Shaker A Mousa
  • Abdelhadi Rebbaa
  • Xin Zheng
  • Fei Chu
  • Christine Gallati
  • Usawadee Dier
  • Thangirala Sudha
  • Bernard L Mirkin
  • Olfat Shaker
  • Pauline M Chou
  • Murat Yalcin
  • Evgeny Dyskin
  • Christine Bianchini

Detail Information

Publications3

  1. ncbi Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy
    Xin Zheng
    Children s Memorial Research Center, Children s Memorial Hospital, Department of Pediatrics, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Biochim Biophys Acta 1783:2294-300. 2008
    ..Overall, these findings suggest that a hierarchy between pro-survival and pro-death proteases may have important consequences on cell fate...
  2. pmc Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism
    Xin Zheng
    Department of Pediatrics, Children s Memorial Research Center, Children s Memorial Hospital, Chicago, IL, USA
    Am J Physiol Cell Physiol 296:C65-74. 2009
    ....
  3. ncbi The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor
    Abdelhadi Rebbaa
    The Pharmaceutical Research Institute at Albany, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA
    Anticancer Res 29:4473-81. 2009
    ..Together, these findings provide evidence that cathepsin L plays an important role in angiogenesis and suggest that NSITC represents a potential drug for the treatment of aggressive cancer...